Pulmatrix Inc (PULM)

$1.31 -0.01 (-0.76%)
Market Cap 4.79M
Revenue (ttm) 0.00
Net Income (ttm) -5.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 25,100
Avg Vol 50,754
Day's Range N/A - N/A
Shares Out 3.65M
Stochastic %K 9%
Beta 1.97
Analysts Strong Buy
Price Target $10.00

Company Profile

Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical tri...

Industry: Biotechnology
Sector: Healthcare
Phone: 888 355 4440
Address:
945 Concord Street, Suite 1217, Framingham, United States
HomeRunHitterXXXXX
HomeRunHitterXXXXX Apr. 4 at 2:05 PM
$PULM PUlM gave this away free and it’s still selling total bs
0 · Reply
Nakom
Nakom Apr. 2 at 2:55 PM
$PULM JMO but this feels like some people who shorted are getting real nervous. No reason to sell if you have waited this long. Everything should play out in July/August. That’s not that far away.
0 · Reply
hiTHit
hiTHit Apr. 1 at 5:04 PM
$PULM In three months, the price will be $20. It would be better for you to buy this stock in three months rather than now.🤓
1 · Reply
Nakom
Nakom Apr. 1 at 3:18 PM
$PULM CAN YOU SAY TRAPPED. 🤣🤣🤣
0 · Reply
Nakom
Nakom Apr. 1 at 2:32 PM
$PULM I wonder when these retail investors who shorted the stock will realize they missed the real story. You might’ve been able to short in the past, but this is a different story and a different ending.
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Apr. 1 at 1:49 PM
$PULM no sellers just corrupt trading on ask imo sent to sec
0 · Reply
marketsinshambles
marketsinshambles Apr. 1 at 12:07 PM
$PULM This POS is total trash. Been that way from day one. If you are holding this 💩get a mental health screening
0 · Reply
anatoma1
anatoma1 Mar. 31 at 7:48 PM
$PULM Only difference is that with the Cullgen merger they announced dividends to be paid out with sale of assets. After the current merger, Pulm ownership of the combined company is higher than the previous time. Idiots just read the 6% ownership and run. What were they thinking? The assets just disappeared? The buyers of the assets are insisting on concurrent closing with the merger. The merger announcement should have made mention of the asset sale.
2 · Reply
Nakom
Nakom Mar. 31 at 6:34 PM
$PULM If you shorted good luck finding a lot of shares to cover. 🤣🤣🤣
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Mar. 31 at 1:36 PM
$PULM the stock price is down 100% since they announced new merger wtf did these clowns just do to shareholders?
0 · Reply
Latest News on PULM
Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Mar 26, 2026, 8:00 AM EDT - 10 days ago

Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Mar 2, 2026, 8:00 AM EST - 4 weeks ago

Pulmatrix Announces Termination of Prior Planned Merger and Continues Pursuit of Alternative Merger Opportunities

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Feb 26, 2026, 8:05 AM EST - 5 weeks ago

Pulmatrix Announces Year-End and Fourth Quarter 2025 Financial Results

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Dec 18, 2025, 8:05 AM EST - 3 months ago

Pulmatrix and Cullgen Continue to Pursue Merger While Granting Each Other Waivers to Explore Alternatives

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Oct 16, 2025, 8:05 AM EDT - 6 months ago

Pulmatrix Announces Third Quarter 2025 Financial Results and Divestment Plan for Migraine and Inhalation Assets

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Aug 6, 2025, 8:05 AM EDT - 8 months ago

Pulmatrix Announces Second Quarter 2025 Financial Results and Divestment Plan for Inhalation Assets

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

May 15, 2025, 8:05 AM EDT - 11 months ago

Pulmatrix Announces First Quarter 2025 Financial Results and Divestment Plan for Assets

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

May 9, 2025, 4:00 PM EDT - 11 months ago

PULMATRIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Pulmatrix, Inc. - PULM

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

Mar 21, 2025, 8:05 AM EDT - 1 year ago

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

Nov 15, 2024, 8:00 AM EST - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PULM and ENTO on Behalf of Shareholders

GRDX

Pulmatrix and Cullgen Announce Proposed Merger

Nov 13, 2024, 9:00 AM EST - 1 year ago

Pulmatrix and Cullgen Announce Proposed Merger

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 8, 2024, 10:26 AM EST - 1 year ago

Pulmatrix Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 13, 2024, 9:05 AM EDT - 1 year ago

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

May 29, 2024, 8:45 AM EDT - 2 years ago

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation

MNKD

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

May 15, 2024, 9:35 AM EDT - 2 years ago

Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100)

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 10, 2024, 8:05 AM EDT - 2 years ago

Pulmatrix Announces First Quarter 2024 Financial Results and Provides Corporate Update

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Mar 28, 2024, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Year-End and Q4 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Jan 8, 2024, 9:00 AM EST - 2 years ago

Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 9, 2023, 9:05 AM EST - 2 years ago

Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Sep 19, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Aug 23, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Jul 11, 2023, 9:05 AM EDT - 2 years ago

Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Jun 15, 2023, 9:20 AM EDT - 3 years ago

Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting of the American Headache Society

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

May 24, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Selected to Present at the Annual Biotechnology Innovation Organization (BIO) International Convention

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

May 12, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces First Quarter 2023 Financial Results and Provides Corporate Update

Pulmatrix Supports World Asthma Day 2023

May 2, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Supports World Asthma Day 2023

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Mar 30, 2023, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Year-End and Q4 Financial 2022 Results and Provides Corporate Update

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Feb 6, 2023, 9:10 AM EST - 3 years ago

Pulmatrix Announces First Patient Dosed in Phase 2b Study of PUR1900 for Treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in Subjects with Asthma

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Jan 25, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Host Key Opinion Leader Webinar "PUR3100 for the Treatment of Acute Migraine: Unlocking the Potential of DHE Treatment"

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Jan 23, 2023, 9:05 AM EST - 3 years ago

Pulmatrix to Present Data on PUR1800 at the Annual Meeting of the American Academy of Allergy, Asthma and Immunology

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Jan 4, 2023, 9:05 AM EST - 3 years ago

Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100, a Novel Orally Inhaled Dihydroergotamine (DHE), for Acute Migraine

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 10, 2022, 9:05 AM EST - 3 years ago

Pulmatrix Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Sep 26, 2022, 9:00 AM EDT - 3 years ago

Pulmatrix Announces Patient Dosing Completed for its Novel Inhaled Therapy PUR3100 for Acute Migraine

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Aug 8, 2022, 9:05 AM EDT - 3 years ago

Pulmatrix Announces Second Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Jul 12, 2022, 9:00 AM EDT - 4 years ago

Pulmatrix Announces First Subject Dosed in Phase 1 Study of PUR3100 for Acute Migraine

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

May 12, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Mar 29, 2022, 9:05 AM EDT - 4 years ago

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Mar 21, 2022, 12:45 PM EDT - 4 years ago

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Mar 21, 2022, 8:05 AM EDT - 4 years ago

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Mar 17, 2022, 4:05 PM EDT - 4 years ago

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Mar 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Feb 24, 2022, 4:05 PM EST - 4 years ago

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

Pulmatrix Issues Letter to Stockholders

Feb 1, 2022, 9:00 AM EST - 4 years ago

Pulmatrix Issues Letter to Stockholders

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Dec 17, 2021, 4:30 PM EST - 4 years ago

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

Pulmatrix Announces $6.75 Million Registered Direct Offering

Dec 15, 2021, 8:00 AM EST - 4 years ago

Pulmatrix Announces $6.75 Million Registered Direct Offering

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

Nov 10, 2021, 4:15 PM EST - 4 years ago

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

HomeRunHitterXXXXX
HomeRunHitterXXXXX Apr. 4 at 2:05 PM
$PULM PUlM gave this away free and it’s still selling total bs
0 · Reply
Nakom
Nakom Apr. 2 at 2:55 PM
$PULM JMO but this feels like some people who shorted are getting real nervous. No reason to sell if you have waited this long. Everything should play out in July/August. That’s not that far away.
0 · Reply
hiTHit
hiTHit Apr. 1 at 5:04 PM
$PULM In three months, the price will be $20. It would be better for you to buy this stock in three months rather than now.🤓
1 · Reply
Nakom
Nakom Apr. 1 at 3:18 PM
$PULM CAN YOU SAY TRAPPED. 🤣🤣🤣
0 · Reply
Nakom
Nakom Apr. 1 at 2:32 PM
$PULM I wonder when these retail investors who shorted the stock will realize they missed the real story. You might’ve been able to short in the past, but this is a different story and a different ending.
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Apr. 1 at 1:49 PM
$PULM no sellers just corrupt trading on ask imo sent to sec
0 · Reply
marketsinshambles
marketsinshambles Apr. 1 at 12:07 PM
$PULM This POS is total trash. Been that way from day one. If you are holding this 💩get a mental health screening
0 · Reply
anatoma1
anatoma1 Mar. 31 at 7:48 PM
$PULM Only difference is that with the Cullgen merger they announced dividends to be paid out with sale of assets. After the current merger, Pulm ownership of the combined company is higher than the previous time. Idiots just read the 6% ownership and run. What were they thinking? The assets just disappeared? The buyers of the assets are insisting on concurrent closing with the merger. The merger announcement should have made mention of the asset sale.
2 · Reply
Nakom
Nakom Mar. 31 at 6:34 PM
$PULM If you shorted good luck finding a lot of shares to cover. 🤣🤣🤣
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Mar. 31 at 1:36 PM
$PULM the stock price is down 100% since they announced new merger wtf did these clowns just do to shareholders?
0 · Reply
Nakom
Nakom Mar. 31 at 1:15 PM
$PULM Lots of M&A going on right now. Don’t get caught up in the merger. It’s all about the sale of the assets
1 · Reply
Cripes84
Cripes84 Mar. 31 at 12:55 PM
$PULM Rebound
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Mar. 31 at 12:19 PM
$PULM so what is the shareholder value after merger did Ludwig just f the shareholders even more with this merger? How do PULM shareholders end up with 6% of new company? What kind of idiot makes this deal and says it’s good for PULM shareholders. Unless the new company opens up at at over 50.
0 · Reply
HomeRunHitterXXXXX
HomeRunHitterXXXXX Mar. 30 at 8:23 PM
$PULM what happens to 4 mil cash they have?
2 · Reply
marketsinshambles
marketsinshambles Mar. 30 at 6:58 PM
$PULM This SCAM still trading?🤣🤣🤣
0 · Reply
Nakom
Nakom Mar. 30 at 6:45 PM
$PULM had to add another 100 shares. Just could not resist.
2 · Reply
texrex1230
texrex1230 Mar. 30 at 5:09 PM
$PULM Here is my conspiracy theory on what is going with PULM: Big Pharma wants people to stay sick so they can make more money off of them. Recent news had a story on the CIA classified a Russian medical report on a possible cure for cancer back in 1951. A reliable source says that Big Pharma has cures for cancer, diabetes, chronic illnesses, autoimmune disorders, dementia, and Alzheimer’s. Big Pharma, the FDA, and the CDC knows how useful Isperse is in delivering medicine into the bloodstream via the lungs. So they arranged for Ted to become CEO so he can destroy PULM from the inside. Meanwhile, they had their buddies in the financial world (Blackrock, Vanguard, and State Street) short the stock until it became a penny stock. For what purpose? So they can get their hands on Isperse for the cheapest price and bury it in their vaults. Eos SENOLYTIX is just a stepping stone to get to their diabolical end of Isperse.
1 · Reply
Nakom
Nakom Mar. 30 at 4:06 PM
$PULM Picked up another 95 shares. Thanks for the cheap shares.
1 · Reply
MinnieSteve3
MinnieSteve3 Mar. 30 at 3:53 PM
$PULM Curious. When the Cullgen merger was first announced, the stock took off. With the announcement of the Eos SENOLYTIX merger, the stock collapsed. Are the deals that much different?
1 · Reply
MinnieSteve3
MinnieSteve3 Mar. 30 at 1:52 PM
$PULM Market cap (@$1.32/share) is now $4.82 million. Honestly, there is no interest in iSPERSE or the pipeline assets?
1 · Reply
Nakom
Nakom Mar. 30 at 9:53 AM
$PULM It will be interesting to see if we get an S 4 in April.
0 · Reply
MinnieSteve3
MinnieSteve3 Mar. 29 at 5:48 PM
$PULM Short interest at 3/13 was 2,505 shares, the lowest in the last 12 months and maybe the lowest ever. This was prior to the new merger proposal and the recent share drop.
1 · Reply